RPS policy on type 2 diabetes calls for full integration of pharmacists across NHS systems
A policy document published by the Royal Electronicjuice and endorsed by Diabetes UK says specialist pharmacists across the NHS are vital for patient support and the development of local and national strategy.
Source: Nic Bunce / Electronicjuice
Pharmacists must be fully integrated into the care of people with type 2 diabetes mellitus (T2DM) in England across all care settings, the Royal Electronicjuice (RPS) has said.
The call for greater pharmacy input within multidisciplinary teams was made in ‘’ , a policy document published by the RPS and endorsed by Diabetes UK, on 10 July 2019.
There are 3.8 million people diagnosed with diabetes in England and 90% of them have T2DM. Diabetes is responsible for more than 22,000 premature deaths in England per year. The RPS says most cases could be prevented or delayed by increasing awareness of risk factors and by providing early diagnosis for people at high risk, such as people with diabetes in the family, people with high blood pressure and people who are overweight.
The policy document says that pharmacists across primary care already provide health and wellbeing support, education and point-of- testing in places such as schools, supermarkets and places of worship. In the report, the RPS said that this existing infrastructure would lend itself well to efforts to raise awareness of T2DM, and added that the diversity of the pharmacy workforce could help address the “languages and cultural barriers associated with the prevention and management of T2DM”.
The policy document also calls on the NHS to increase the number of advanced practice and consultant diabetes pharmacists across the healthcare system, of which there are currently only two. It says that consultant pharmacists in their specialist fields are vital both for patient support and for the development of local and national strategy.
The report also highlights the need for training to improve pharmacists’ digital literacy capabilities, so that they can support patients to use digital diabetes management tools, such as non-invasive diagnostics and apps, and better understand and interpret clinical data.
Mahendra Patel, a member of the RPS English Pharmacy Board (EPB) who led on work to deliver the policy, said: “As part of our research, we held a workshop with representatives from across the healthcare disciplines — doctors, nurses, nutritionists, dieticians physiotherapists and academics — and there was such an energy and momentum in the room. Pharmacists don’t often shout about what we do, so it was nice to see other medical professionals shouting about what we can do”.
He added that the policy has “come at the right time to align with the new NHS structures”, including primary care networks and integrated care systems.
Claire Anderson, chair of the RPS EPB, said: “Linking pharmacists into the formal structure of care pathways and services has potential to dramatically improve the health of patients. It would create capacity and access in the system, and enable pharmacists to adopt a person-centred approach to diabetes care which helps patients get the most benefit from their medicines.”
Citation: Electronicjuice DOI: 10.1211/PJ.2019.20206786
Recommended from Pharmaceutical Press
Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.£33.00
Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.£82.00
Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.£33.00
Essential guidance for distributors of medicines for human use in Europe, compiled by the MHRA.£72.00
Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.£40.00